# SLC6A9

## Overview
The SLC6A9 gene encodes the protein solute carrier family 6 member 9, commonly known as glycine transporter 1 (GlyT1). This protein is a member of the solute carrier family 6, which is characterized by its role in neurotransmitter transport across cell membranes. GlyT1 is a transmembrane protein that plays a critical role in the central nervous system by regulating glycine levels in the synaptic cleft. It is primarily expressed in glial cells and is essential for modulating neurotransmission, particularly in relation to N-methyl-D-aspartate (NMDA) receptor activity. The transporter's function involves the co-transport of glycine with sodium and chloride ions, utilizing the sodium gradient to facilitate this process. Dysregulation of GlyT1 has been linked to various neurological disorders, underscoring its importance in maintaining synaptic balance and proper neuronal function (Pramod2013SLC6; Marques2020Neurobiology).

## Structure
The SLC6A9 gene encodes a glycine transporter protein, which is part of the solute carrier family 6. This protein typically features 12 transmembrane domains, a characteristic shared with other neurotransmitter transporters (Betz2006Glycine). The primary structure of SLC6A9 includes conserved motifs essential for substrate binding and transport, which are crucial for its function as a glycine transporter (Pramod2013SLC6).

The secondary structure of SLC6A9 is organized into a 5 + 5 helical architecture, where transmembrane segments form two pentahelical bundles aligned antiparallel, creating a pseudo two-fold axis of symmetry. This arrangement is typical of the LeuT-fold, a common structural motif in the SLC6 family (Pramod2013SLC6).

Post-translational modifications, such as glycosylation, may influence the stability and function of the SLC6A9 protein. These modifications are important for the proper folding and trafficking of the transporter (Freissmuth2017SLC6). Additionally, splice variants of SLC6A9 can result in isoforms with differing regulatory properties, potentially affecting the transporter's function and localization (Betz2006Glycine). The protein's structure and modifications are integral to its role in glycine uptake and neurotransmission.

## Function
The SLC6A9 gene encodes the glycine transporter 1 (GlyT1), a crucial protein for regulating glycine levels in the central nervous system. GlyT1 is primarily expressed in glial cells, such as astrocytes, and is involved in the uptake of glycine from the synaptic cleft, which is essential for modulating neurotransmission (Pramod2013SLC6; Marques2020Neurobiology). Glycine acts as both an inhibitory neurotransmitter and a co-agonist with glutamate at N-methyl-D-aspartate (NMDA) receptors, playing a significant role in excitatory neurotransmission (Alfallaj2019Glycine; Marques2020Neurobiology).

GlyT1 operates by co-transporting two sodium ions and one chloride ion along with glycine, utilizing the sodium gradient maintained by Na+/K+ ATPase to drive this process (Marques2020Neurobiology). This transporter is vital for maintaining low extracellular glycine levels, which is crucial for proper synaptic transmission and neurotransmitter regulation (Rudnick2013The). GlyT1's activity is essential for the clearance of synaptic glycine, thereby terminating glycinergic transmission and maintaining the balance of pre- and postsynaptic activity (Marques2020Neurobiology). Dysfunction in GlyT1 is associated with various neurological disorders, highlighting its importance in normal neuronal function (Pramod2013SLC6).

## Clinical Significance
Mutations in the SLC6A9 gene, which encodes the glycine transporter 1 (GLYT1), have been linked to a novel form of nonketotic hyperglycinemia. This condition is characterized by neonatal onset, respiratory failure, severe hypotonia, limb hypertonicity, and startle-like responses to stimuli. Patients also exhibit dysmorphic features, musculoskeletal abnormalities, and elevated glycine levels in cerebrospinal fluid, with a high cerebrospinal fluid to plasma glycine ratio. Diagnosis is confirmed through genetic testing for SLC6A9 mutations, and management is supportive as no curative treatment exists (Alfadhel2016Mutation; Yahyaoui2019Amino).

Alterations in SLC6A9 expression have been associated with essential hypertension. Variants in the gene have been identified as potential susceptibility loci for this condition, suggesting a role in blood pressure regulation through the sympathetic nervous system (Ueno2009Association).

SLC6A9 has also been implicated in methamphetamine-use disorder. Specific single nucleotide polymorphisms (SNPs) in the gene have been associated with increased risk for the disorder, indicating that genetic variations in SLC6A9 may contribute to individual vulnerability to substance dependence (Morita2007The).

## Interactions
The SLC6A9 gene encodes the glycine transporter 1 (GlyT1), which is involved in neurotransmitter transport in the central nervous system. GlyT1 interacts with various proteins that influence its function and regulation. One notable interaction is with PSD-95, a protein that stabilizes GlyT1 at the cell surface, thereby playing a role in regulating extracellular glycine concentration around NMDA receptors (Kristensen2011SLC6). This interaction is crucial for synaptic localization and function, impacting neurotransmitter balance and synaptic transmission.

GlyT1 is also part of the glycine transport system, which is essential for maintaining neurotransmitter homeostasis. Although specific interactions with proteins like syntaxin 1A are not detailed in the provided context, GlyT1's role in the glycine receptor complex suggests it may participate in multiprotein complexes that modulate synaptic transmission and neuronal communication. The regulation of GlyT1 through these interactions is significant for its function in neurotransmitter uptake and its potential implications in neurological disorders such as schizophrenia and cognitive disorders (Pramod2013SLC6). The complexity of these interactions highlights the importance of GlyT1 in maintaining proper neurotransmitter levels and synaptic function.


## References


[1. (Kristensen2011SLC6) Anders S. Kristensen, Jacob Andersen, Trine N. Jørgensen, Lena Sørensen, Jacob Eriksen, Claus J. Loland, Kristian Strømgaard, and Ulrik Gether. Slc6 neurotransmitter transporters: structure, function, and regulation. Pharmacological Reviews, 63(3):585–640, July 2011. URL: http://dx.doi.org/10.1124/pr.108.000869, doi:10.1124/pr.108.000869. This article has 679 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1124/pr.108.000869)

[2. (Alfadhel2016Mutation) Majid Alfadhel, Marwan Nashabat, Hanan Al Qahtani, Ahmed Alfares, Fuad Al Mutairi, Hesham Al Shaalan, Ganka V. Douglas, Klaas Wierenga, Jane Juusola, Muhammad Talal Alrifai, Stefan T. Arold, Fowzan Alkuraya, and Qais Abu Ali. Mutation in slc6a9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Human Genetics, 135(11):1263–1268, August 2016. URL: http://dx.doi.org/10.1007/s00439-016-1719-x, doi:10.1007/s00439-016-1719-x. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00439-016-1719-x)

[3. (Alfallaj2019Glycine) Rayan Alfallaj and Majid Alfadhel. Glycine transporter 1 encephalopathy from biochemical pathway to clinical disease: review. Child Neurology Open, January 2019. URL: http://dx.doi.org/10.1177/2329048X19831486, doi:10.1177/2329048x19831486. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1177/2329048X19831486)

[4. (Betz2006Glycine) H. Betz, J. Gomeza, W. Armsen, P. Scholze, and V. Eulenburg. Glycine transporters: essential regulators of synaptic transmission. Biochemical Society Transactions, 34(1):55–58, January 2006. URL: http://dx.doi.org/10.1042/bst0340055, doi:10.1042/bst0340055. This article has 107 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst0340055)

[5. (Ueno2009Association) Takahiro Ueno, Yasuharu Tabara, Noboru Fukuda, Kazunobu Tahira, Taro Matsumoto, Kotoko Kosuge, Akira Haketa, Koichi Matsumoto, Yuichi Sato, Tomohiro Nakayama, Tomohiro Katsuya, Toshio Ogihara, Yoshio Makita, Akira Hata, Michiko Yamada, Norio Takahashi, Nobuhito Hirawa, Satosh Umemura, Tetsuro Miki, and Masayoshi Soma. Association of slc6a9 gene variants with human essential hypertension. Journal of Atherosclerosis and Thrombosis, 16(3):201–206, 2009. URL: http://dx.doi.org/10.5551/JAT.E125, doi:10.5551/jat.e125. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.5551/JAT.E125)

[6. (Pramod2013SLC6) Akula Bala Pramod, James Foster, Lucia Carvelli, and L. Keith Henry. Slc6 transporters: structure, function, regulation, disease association and therapeutics. Molecular Aspects of Medicine, 34(2–3):197–219, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.07.002, doi:10.1016/j.mam.2012.07.002. This article has 233 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.07.002)

[7. (Freissmuth2017SLC6) Michael Freissmuth, Thomas Stockner, and Sonja Sucic. SLC6 Transporter Folding Diseases and Pharmacochaperoning, pages 249–270. Springer International Publishing, 2017. URL: http://dx.doi.org/10.1007/164_2017_71, doi:10.1007/164_2017_71. This article has 29 citations.](https://doi.org/10.1007/164_2017_71)

[8. (Marques2020Neurobiology) Bruno Lemes Marques, Onésia Cristina Oliveira-Lima, Gustavo Almeida Carvalho, Raphaela de Almeida Chiarelli, Raul Izidoro Ribeiro, Ricardo Cambraia Parreira, Elis Marra da Madeira Freitas, Rodrigo Ribeiro Resende, Friederike Klempin, Henning Ulrich, Renato Santiago Gomez, and Mauro Cunha Xavier Pinto. Neurobiology of glycine transporters: from molecules to behavior. Neuroscience &amp; Biobehavioral Reviews, 118:97–110, November 2020. URL: http://dx.doi.org/10.1016/j.neubiorev.2020.07.025, doi:10.1016/j.neubiorev.2020.07.025. This article has 34 citations.](https://doi.org/10.1016/j.neubiorev.2020.07.025)

[9. (Yahyaoui2019Amino) Raquel Yahyaoui and Javier Pérez-Frías. Amino acid transport defects in human inherited metabolic disorders. International Journal of Molecular Sciences, 21(1):119, December 2019. URL: http://dx.doi.org/10.3390/ijms21010119, doi:10.3390/ijms21010119. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21010119)

[10. (Rudnick2013The) Gary Rudnick, Reinhard Krämer, Randy D. Blakely, Dennis L. Murphy, and Francois Verrey. The slc6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction. Pflügers Archiv - European Journal of Physiology, 466(1):25–42, December 2013. URL: http://dx.doi.org/10.1007/s00424-013-1410-1, doi:10.1007/s00424-013-1410-1. This article has 130 citations.](https://doi.org/10.1007/s00424-013-1410-1)

[11. (Morita2007The) Yukitaka Morita, Hiroshi Ujike, Yuji Tanaka, Makiko Kishimoto, Yuko Okahisa, Tatsuya Kotaka, Mutsuo Harano, Toshiya Inada, Tokutaro Komiyama, Toru Hori, Mitsuhiko Yamada, Yoshimoto Sekine, Nakao Iwata, Masaomi Iyo, Ichiro Sora, Norio Ozaki, and Shigetoshi Kuroda. The glycine transporter 1 gene (glyt1) is associated with methamphetamine‐use disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B(1):54–58, June 2007. URL: http://dx.doi.org/10.1002/ajmg.b.30565, doi:10.1002/ajmg.b.30565. This article has 19 citations.](https://doi.org/10.1002/ajmg.b.30565)